TY - JOUR
T1 - Beyond VEGF
T2 - Inhibition of the fibroblast growth factor pathway and antiangiogenesis
AU - Lieu, Christopher
AU - Heymach, John
AU - Overman, Michael
AU - Tran, Hai
AU - Kopetz, Scott
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Fibroblast growth factor (FGF) signaling regulates cell proliferation, differentiation, survival, angiogenesis, and wound healing. Compelling evidence for deregulated FGF signaling in tumorigenesis continues to emerge, and a growing body of research suggests that FGF may also play an integral role in the resistance to anti-VEGF therapy. Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients.
AB - Fibroblast growth factor (FGF) signaling regulates cell proliferation, differentiation, survival, angiogenesis, and wound healing. Compelling evidence for deregulated FGF signaling in tumorigenesis continues to emerge, and a growing body of research suggests that FGF may also play an integral role in the resistance to anti-VEGF therapy. Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=80053493427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053493427&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-11-0659
DO - 10.1158/1078-0432.CCR-11-0659
M3 - Review article
C2 - 21953501
AN - SCOPUS:80053493427
SN - 1078-0432
VL - 17
SP - 6130
EP - 6139
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 19
ER -